Consolidated Statements of Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development expenses	$ 20,700	$ 17,104
Selling, general and administrative expenses	74,516	68,495
Restructuring expense (income)	3,345	(53)
Total operating expenses	98,561	85,546
Operating loss	(98,561)	(85,546)
Investment and other (expense) income, net	(536)	2,343
Interest expense	(12,342)	(9,942)
Loss before income taxes	(111,439)	(93,145)
Income tax provision (benefit)	26,025	(15,816)
Net loss	$ (137,464)	$ (77,329)
Net loss per share
Net loss per share - basic (in usd per share)	$ (2.29)	$ (1.32)
Net loss per share - diluted (in usd per share)	$ (2.29)	$ (1.32)
Weighted average number of shares outstanding
Weighted average number of shares outstanding - basic (in shares)	60,094	58,535
Weighted average number of shares outstanding - diluted (in shares)	60,094	58,535